Details for Patent: 8,637,512

« Back to Dashboard

Which drugs does patent 8,637,512 protect, and when does it expire?

Patent 8,637,512 protects LAMICTAL XR and is included in one NDA.

This patent has forty-four patent family members in thirty countries.

Summary for Patent: 8,637,512

Title:	Formulations and method of treatment
Abstract:	A sustained release formulation of lamotrigine or a pharmaceutically acceptable derivative thereof and methods of treatment and uses thereof.
Inventor(s):	Ian Richard Buxton, Wlodzimierz Karolak, Mehran Maleki, Vijay Mohan Iyer
Assignee:	Glaxo Group Ltd
Application Number:	US10/726,752
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,637,512
Patent Claim Types: see list of patent claims	Composition; Formulation; Compound; Dosage form;

Drugs Protected by US Patent 8,637,512

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Glaxosmithkline Llc	LAMICTAL XR	lamotrigine	TABLET, EXTENDED RELEASE;ORAL	022115-001	May 29, 2009	AB	RX	Yes	No	8,637,512		Y
Glaxosmithkline Llc	LAMICTAL XR	lamotrigine	TABLET, EXTENDED RELEASE;ORAL	022115-002	May 29, 2009	AB	RX	Yes	Yes	8,637,512		Y
Glaxosmithkline Llc	LAMICTAL XR	lamotrigine	TABLET, EXTENDED RELEASE;ORAL	022115-003	May 29, 2009	AB	RX	Yes	No	8,637,512		Y
Glaxosmithkline Llc	LAMICTAL XR	lamotrigine	TABLET, EXTENDED RELEASE;ORAL	022115-004	May 29, 2009	AB	RX	Yes	Yes	8,637,512		Y

Foreign Priority and PCT Information for Patent: 8,637,512

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	0217492.8	Jul 29, 2002
United Kingdom	0217493.6	Jul 29, 2002
United Kingdom	0313801.3	Jun 13, 2003

International Family Members for US Patent 8,637,512

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	040709
Austria	424827
Australia	2003260336
Brazil	0313148